Our findings showed that rh-endostatin could improve the antitumor effects of CIK cells and suggested that combination therapy with rh-endostatin and CIK cells held great promise in the treatment of advanced stage lung cancer patients. This evidence concerns the gene COL18A1 and lung cancer.